Skip to main content
TipRanks
Go Ultimate75% OFF

Grifols (0RDU) AI Stock Analysis

5 Followers
GB:0RDU

Grifols

(LSE:0RDU)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Improving Revenue and MarginsRevenue expansion alongside stronger EBIT and EBITDA margins indicates improving operating scale and execution. If maintained, this combination can support higher internal funding, reinforce the company’s position in plasma-derived therapies, and provide a stronger base for durable earnings growth.
Negative Factors
Elevated LeverageHistorically high leverage can constrain capital allocation and leave less flexibility for investment or unexpected operating pressure. It also increases sensitivity to refinancing conditions and interest costs, making balance-sheet management an important limitation on otherwise improving operations.

Grifols (0RDU) vs. iShares MSCI United Kingdom ETF (EWC)

-20%-10%0%10%20%30%GB:0RDU+13.71%EWC+18.88%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 6.93B
Dividend Yield
0.71%
Average Volume (3M)
30.66K
Price to Earnings (P/E)
16.1
Beta (1Y)
0.99
Revenue Growth
1.03%
EPS Growth
30.59%
Country
UK
Employees
25,000
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - General

Grifols Business Overview & Revenue Model

Company Description

Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from pl...

Grifols Risk Analysis

Grifols disclosed 53 risk factors in its most recent earnings report. Grifols reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Grifols Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

GB:0RDU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ES:ROVIES:ROVI76OutperformEUR 3.52B17.3129.17%1.38%14.41%69.69%
ES:ALMES:ALM70OutperformEUR 2.32B31.694.81%1.73%9.67%174.00%
ES:FAEES:FAE69NeutralEUR 1.58B11.6818.19%2.52%31.88%-20.09%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
ES:RJFES:RJF47NeutralEUR 214.07M30.703.14%0.75%-0.42%4.56%

* General Sector Average

Performance Comparison

0%20%40%GB:0RDUES:ALMES:FAEES:RJFES:ROVIES:IKMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0RDU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0RDUGrifols (0RDU)11.621.4213.93%
ES:ALMAlmirall SA10.64-1.50-12.35%
ES:FAEFaes Farma5.080.5812.89%
ES:RJFLABORATORIO REIG JOFRE2.60-0.05-1.92%
ES:ROVILaboratorios Farmaceuticos Rovi69.6012.1621.17%
ES:IKM1nKemia IUCT Group SA0.310.000.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.